Orexo: Zubsolv Rx Data week 9, 2017

Zubsolv tablets showed a market share of 5.49% (5.50%), 4-week rolling average. The total number of Zubsolv tablets sold week 9 (8) reaching 330,203 (308,626). Zubsolv prescriptions (TRx) recorded a market share of 5.50% (5.53%), 4-week rolling average. Number of TRx reaching 11,503 (11,164) during the week. The overall market (buprenorphine/naloxone) show-ed a y/y growth rate of 9.2% (9.0%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 11.2% (11.3%) (4-week rolling average).

Going forward, we will go down in intensity, and only publish prescription data on a monthly basis.

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-06 Update
2017-03-06 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-01 Update
2017-02-28 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update